These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 17095587

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists.
    Sullivan SK, Brown MS, Gao Y, Loweth CJ, Lio FM, Crowe PD, Struthers RS, Betz SF.
    Biochemistry; 2006 Dec 26; 45(51):15327-37. PubMed ID: 17176055
    [Abstract] [Full Text] [Related]

  • 4. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902).
    Struthers RS, Chen T, Campbell B, Jimenez R, Pan H, Yen SS, Bozigian HP.
    J Clin Endocrinol Metab; 2006 Oct 26; 91(10):3903-7. PubMed ID: 16849403
    [Abstract] [Full Text] [Related]

  • 5. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats.
    Anderes KL, Luthin DR, Castillo R, Kraynov EA, Castro M, Nared-Hood K, Gregory ML, Pathak VP, Christie LC, Paderes G, Vazir H, Ye Q, Anderson MB, May JM.
    J Pharmacol Exp Ther; 2003 May 26; 305(2):688-95. PubMed ID: 12606616
    [Abstract] [Full Text] [Related]

  • 6. 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization.
    Tucci FC, Zhu YF, Struthers RS, Guo Z, Gross TD, Rowbottom MW, Acevedo O, Gao Y, Saunders J, Xie Q, Reinhart GJ, Liu XJ, Ling N, Bonneville AK, Chen T, Bozigian H, Chen C.
    J Med Chem; 2005 Feb 24; 48(4):1169-78. PubMed ID: 15715483
    [Abstract] [Full Text] [Related]

  • 7. Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism.
    Sullivan SK, Hoare SR, Fleck BA, Zhu YF, Heise CE, Struthers RS, Crowe PD.
    Biochem Pharmacol; 2006 Sep 28; 72(7):838-49. PubMed ID: 16930559
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
    Betz SF, Reinhart GJ, Lio FM, Chen C, Struthers RS.
    J Med Chem; 2006 Jan 26; 49(2):637-47. PubMed ID: 16420049
    [Abstract] [Full Text] [Related]

  • 12. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S, Cho N, Nara Y, Harada M, Endo S, Suzuki N, Furuya S, Fujino M.
    J Med Chem; 2003 Jan 02; 46(1):113-24. PubMed ID: 12502365
    [Abstract] [Full Text] [Related]

  • 13. Development of gonadotrope desensitization to gonadotropin-releasing hormone (GnRH) and recovery are not coupled to inositol phosphate production or GnRH receptor number.
    Hawes BE, Conn PM.
    Endocrinology; 1992 Dec 02; 131(6):2681-9. PubMed ID: 1332845
    [Abstract] [Full Text] [Related]

  • 14. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys.
    Hara T, Araki H, Kusaka M, Harada M, Cho N, Suzuki N, Furuya S, Fujino M.
    J Clin Endocrinol Metab; 2003 Apr 02; 88(4):1697-704. PubMed ID: 12679460
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL.
    J Pharmacol Exp Ther; 2002 Apr 02; 301(1):95-102. PubMed ID: 11907162
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors.
    Tezuka M, Tamai Y, Kuramochi Y, Kobayashi K, Fushimi N, Kiguchi S.
    Clin Exp Pharmacol Physiol; 2022 Oct 02; 49(10):1082-1093. PubMed ID: 35690889
    [Abstract] [Full Text] [Related]

  • 17. Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus.
    Reinhart GJ, Xie Q, Liu XJ, Zhu YF, Fan J, Chen C, Struthers RS.
    J Biol Chem; 2004 Aug 13; 279(33):34115-22. PubMed ID: 15155770
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
    Li H, Anderes KL, Kraynov EA, Luthin DR, Do QQ, Hong Y, Tompkins E, Sun ET, Rajapakse R, Pathak VP, Christie LC, Feng J, Vazir H, Castillo R, Gregory ML, Castro M, Nared-Hood K, Paderes G, Anderson MB.
    J Med Chem; 2006 Jun 01; 49(11):3362-7. PubMed ID: 16722655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.